Optimising biomanufacturing supply chains : Delivering for patients by translating science into differentiated treatments

The pharmaceutical sector is undergoing a paradigm shift as advanced modalities move from research to commercial scale. These innovations, while transformative for patients, introduce unprecedented complexity into biomanufacturing and supply chain operations. Against the backdrop of these scientific innovations, the industry is also experiencing significant complexity driven through an unprecedented policy landscape. This paper examines how Bristol Myers Squibb (BMS) is leveraging data-driven decision making, artificial intelligence (AI), and adaptive workforce strategies to optimise global supply chains. Drawing on recent disruptions — the COVID-19 pandemic, geopolitical events, and technological leaps — the paper provides actionable insights for senior supply chain executives on building resilient, agile, and future-ready supply chains. It emphasises the integration of robust data, transparent supplier networks, and workforce development, offering guidance that transcends sector boundaries. This article is also included in The Business & Management Collection which can be accessed at https://hstalks.com/ business/.